Log In
Print this Print this

Nuwiq, Human-cl rhFVIII, simoctogog alfa

  Manage Alerts
Collapse Summary General Information
Company Octapharma AG
DescriptionRecombinant FVIII (rFVIII) concentrate produced in a genetically modified human embryonic kidney cell line
Molecular Target Factor VIII
Mechanism of ActionProcoagulant
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationHemophilia
Indication DetailsTreat hemophilia A; Treatment and prophylaxis of bleeding in hemophilia A patients
Regulatory Designation EU - Standard Review (Treatment and prophylaxis of bleeding in hemophilia A patients)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today